Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

被引：16
|
作者：
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
79
引用
收藏
页数：9
相关论文
共 50 条
  • [41] Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
    Chari, Ajai
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson Jr, Larry D.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Voorhees, Peter M.
    Usmani, Saad Z.
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [42] Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib plus Lenalidomide plus Dexamethasone or Bortezomib plus Thalidomide plus Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
    Rosinol Dachs, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Rios, Rafael
    Hulin, Cyrille
    Jesus Blanchard, Maria
    Caillot, Denis
    Sureda, Anna
    Hernandez, Miguel T.
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus F.
    Belhadj, Karim
    Jose Lahuerta, Juan
    Chen, Guang
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    Attal, Michel
    BLOOD, 2018, 132
  • [43] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
    Sonneveld, Pieter
    Dimopoulos, Meletios
    Boccadoro, Mario
    Hang Quach
    Ho, P. Joy
    Beksac, Meral
    Hulin, Cyrille
    Antonioli, Elisabetta
    Leleu, Xavier
    Mangiacavalli, Silvia
    Perrot, Aurore
    Cavo, Michele
    Belotti, Angelo
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels
    Liu, Yanfang
    Wang, Jianping
    Sitthi-Amorn, Anna
    de Boer, Carla J.
    Carson, Robin
    Rodriguez-Otero, Paula
    Blade, Joan
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246
  • [44] Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
    Wang, Yin-Che
    Lin, Cheng-Hsien
    Su, Yu-Chen
    Teng, Chieh-Lin Jerry
    HEMATOLOGY, 2025, 30 (01)
  • [45] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
    Hungria, Vania T. M.
    Moura, Fernanda Lemos
    Soares, Paulo
    Lima, Juliana Souza
    Ricci, Lisa Aquaroni
    Nucci, Fabio Moore
    Oliveira Ribeiro, Eduardo Flavio
    Crusoe, Edvan de Queiroz
    Lima, Marinus de Moraes
    Pessoa de Magalhaes Filho, Roberto Jose
    Arrais-Rodrigues, Celso
    Bhaumik, Amitabha
    Parekh, Trilok
    Borgsten, Fredrik
    Carson, Robin
    Trufelli, Damila C.
    Costa, Abel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
  • [46] Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma
    Rosinol, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Tamayo, Rafael Rios
    Hulin, Cyrille
    Blanchard, Maria Jesus
    Caillot, Denis
    Balari, Anna Sureda
    Hernandez, Miguel T.
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus
    Belhadj, Karim
    Lahuerta, Juan-Jose
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    Attal, Michel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E1 - E2
  • [47] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase Ill study (CEPHEUS)
    Zweegman, Sonja
    Usmani, Saad Zafar
    Chastain, Katherine
    Carey, Jodi
    Ren, Karen
    Smith, Elena
    Krevvata, Maria
    Wang, Jianping
    Vermeulen, Jessica
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN
    Silbermann, Rebecca
    Laubach, Jacob
    Kaufman, Jonathan L.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Gries, Katharine S.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Voorhees, Peter M.
    Usmani, Saad Z.
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1257 - 1268
  • [49] Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients With Multiple Myeloma: A Pooled Analaysis of Patients Aged ≥65 Years From Both PERSEUS and GRIFFIN Studies
    Rodriguez-Otero, Paula
    Voorhees, Peter M.
    Boccadoro, Mario
    Laubach, Jacob
    Einsele, Hermann
    Sborov, Douglas W.
    Dimopoulos, Meletios
    Broijl, Annemiek
    Mina, Roberto
    Spencer, Andrew
    Schjesvold, Fredrik
    Silbermann, Rebecca
    Gay, Francesca
    Costa, Luciano
    Perrot, Aurore
    Liu, Yanfang
    Wang, Jianping
    Sitthi-Amorn, Anna
    Carson, Robin
    Cortoos, Annelore
    Usmani, Saad
    Richardson, Paul
    Moreau, Philippe
    Sonneveld, Pieter
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S242 - S243
  • [50] Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Weber, Donna M.
    Thomas, Sheeba K.
    Turturro, Francesco
    Alexanian, Raymond
    Shah, Nina
    Popat, Uday R.
    Nieto, Yago
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Champlin, Richard E.
    Orlowski, Robert Z.
    BLOOD, 2014, 124 (21)
12345